Toll-like Receptor (TLR) Control

(R)-SARM1-IN-5 is the (R)-enantiomer of SARM1-IN-5 (HY-172967). SARM1-IN-5 (compound 1-23-a) is a SARM1 inhibitor. SARM1-IN-5 can be used in the study of axonal degeneration related diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS).

SjDX5-53 control peptide is a control peptide of the TLR2 activator SjDX5-53 (HY-P10982) that does not target a specific receptor and does not modulate regulatory T cells (Tregs) or dendritic cells. SjDX5-53 control peptide can be used to exclude nonspecific effects and help verify the specific role of SjDX5-53 in inducing Tregs and alleviating autoimmune diseases. SjDX5-53 control peptide is used in the study of autoimmune diseases such as colitis and psoriasis.

(R)-Hydroxychloroquine ((R)-HCQ) phosphate is a (R)-isomer of Hydroxychloroquine (HY-W031727). (R)-Hydroxychloroquine inhibits the insulin metabolizing enzyme of cytosolic fraction of liver homogenates in healthy and diabetic rats.

SjDX5-271v is a negative control of SjDX5-271 (HY-P10897). SjDX5-271 is a small 3 kDa peptide. SjDX5-271 inhibits the TLR4/MyD88/NF-κB signaling pathway. SjDX5-271 induces cell polarization. SjDX5-271 alleviats hepatic inflammation. SjDX5-271 protects mice against liver ischemia-reperfusion injury.

(S)-Hydroxychloroquine ((S)-HCQ) sulfate is an isomer of Hydroxychloroquine (HY-W031727). (S)-Hydroxychloroquine sulfate (2.5-20 mg/mL) reduces the rate of insulin degradation in liver homogenates isolated from non-diabetic and diabetic rats. Formulations containing Hydroxychloroquine have been used in the study of malaria, rheumatoid arthritis, and systemic lupus erythematosus.